$14.05
0.00%
Nasdaq, Thu, Oct 17 2024
ISIN
US2537482067
Symbol
DFFN
Sector
Industry

Diffusion Pharmaceuticals Inc. Stock price

$14.05
-2.09 12.95% 1M
-10.95 43.80% 6M
+6.42 84.14% YTD
+5.38 62.05% 1Y
-21.57 60.55% 3Y
-90.95 86.62% 5Y
-39,360.95 99.96% 10Y
Nasdaq, Closing price Thu, Oct 17 2024
+0.00 0.00%
ISIN
US2537482067
Symbol
DFFN
Sector
Industry

Key metrics

Market capitalization $115.97m
Enterprise Value $70.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.35
P/S ratio (TTM) P/S ratio 12.02
P/B ratio (TTM) P/B ratio 2.32
Revenue (TTM) Revenue $9.65m
EBIT (operating result TTM) EBIT $-10.75m
Free Cash Flow (TTM) Free Cash Flow $-3.46m
Cash position $45.09m
EPS (TTM) EPS $-1.79
P/E forward negative
P/S forward 13.39
EV/Sales forward 8.18
Short interest 0.12%
Show more

Is Diffusion Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Diffusion Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Diffusion Pharmaceuticals Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Diffusion Pharmaceuticals Inc. forecast:

Buy
100%

Financial data from Diffusion Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
9.65 9.65
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.17 9.17
5% 5%
95%
- Research and Development Expense 11 11
175% 175%
116%
-11 -11
22% 22%
-111%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -11 -11
22% 22%
-111%
Net Profit -5.04 -5.04
61% 61%
-52%

In millions USD.

Don't miss a Thing! We will send you all news about Diffusion Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Diffusion Pharmaceuticals Inc. Stock News

Neutral
PRNewsWire
about one year ago
Shares of CervoMed to commence trading on Nasdaq under new ticker symbol "CRVO" on August 17, 2023 CervoMed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of dementia with Lewy bodies and other degenerative diseases of the brain CervoMed has a cash runway through Phase 2b clinical data which is expected during 2H 2024 BOSTON , Aug. 16, 2023 /PRNewswire/...
Neutral
GlobeNewsWire
almost 2 years ago
LifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting
Neutral
GlobeNewsWire
almost 2 years ago
CHARLOTTESVILLE, Va., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today sent a letter to its stockholders. The letter highlights the strength, experience and quality of the Company's boa...
More Diffusion Pharmaceuticals Inc. News

Company Profile

Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Head office United States
CEO John Alam
Employees 8
Founded 2001
Website www.cervomed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today